Is cancer biology different in older patients?
Y Van Herck, A Feyaerts, S Alibhai… - The Lancet Healthy …, 2021 - thelancet.com
Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …
often diagnosed at a later stage and might receive less (intensive) treatment, which might …
Polypharmacy and potentially inappropriate medication use in geriatric oncology
Polypharmacy is a highly prevalent problem in older persons, and is challenging to assess
and improve due to variations in definitions of the problem and the heterogeneous methods …
and improve due to variations in definitions of the problem and the heterogeneous methods …
Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study
Background Older adults with advanced cancer are at a high risk for treatment toxic effects.
Geriatric assessment evaluates ageing-related domains and guides management. We …
Geriatric assessment evaluates ageing-related domains and guides management. We …
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
MR Migden, NI Khushalani, ALS Chang… - The lancet …, 2020 - thelancet.com
Background Cemiplimab has shown substantial antitumour activity in patients with
metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous …
metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous …
[HTML][HTML] Understanding treatment tolerability in older adults with cancer
The treatment cannot be worse than the disease is an oft-cited statement representing the
important concept of tolerability; older patients often express concerns about side effects …
important concept of tolerability; older patients often express concerns about side effects …
Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology …
N Denduluri, DA Patt, Y Wang, M Bhor, X Li… - Journal of the National …, 2015 - jnccn.org
Background: A wide variety of myelosuppressive chemotherapy regimens are used for the
treatment of cancer in clinical practice. Neutropenic complications, such as febrile …
treatment of cancer in clinical practice. Neutropenic complications, such as febrile …
Cemiplimab in an elderly frail population of patients with locally advanced or metastatic cutaneous squamous cell carcinoma: a single-center real-life experience from …
Background Cutaneous squamous cell carcinoma (CSCC) is the second most common skin
cancer whose incidence is growing parallel to the lengthening of the average lifespan …
cancer whose incidence is growing parallel to the lengthening of the average lifespan …
Frailty and checkpoint inhibitor toxicity in older patients with melanoma
CP Bruijnen, JJ Koldenhof, RJ Verheijden… - Cancer, 2022 - Wiley Online Library
Background Immune checkpoint inhibitors (ICIs) can cause immune‐related adverse events
(irAEs) that range from mild to life‐threatening. Age itself does not seem to be a predictor for …
(irAEs) that range from mild to life‐threatening. Age itself does not seem to be a predictor for …
Prevention of chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes
J Herrstedt, S Lindberg, PC Petersen - Drugs & aging, 2022 - Springer
Chemotherapy-induced nausea and vomiting (CINV) are still two of the most feared side
effects of cancer therapy. Although major progress in the prophylaxis of CINV has been …
effects of cancer therapy. Although major progress in the prophylaxis of CINV has been …
Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently …
Y Lalami, J Klastersky - Critical reviews in oncology/hematology, 2017 - Elsevier
Despite the overwhelming evidence for the role of granulocyte colony stimulating factors (G-
CSF) in managing febrile neutropenia (FN) risk, chemotherapy-induced neutropenia (CIN) …
CSF) in managing febrile neutropenia (FN) risk, chemotherapy-induced neutropenia (CIN) …